Compile Data Set for Download or QSAR
maximum 50k data
Found 56 Enz. Inhib. hit(s) with all data for entry = 8602
TargetCoagulation factor XI(Homo sapiens (Human))
Ono Pharmaceutical

US Patent
LigandPNGBDBM294112(US10336741, Example 99 | US10882855, Example 99 | ...)
Affinity DataIC50:  1.20nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Ono Pharmaceutical

US Patent
LigandPNGBDBM238259(US10336741, Example 71 | US10882855, Example 71 | ...)
Affinity DataIC50:  2.20nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Ono Pharmaceutical

US Patent
LigandPNGBDBM238268(US10336741, Example 98 | US10882855, Example 98 | ...)
Affinity DataIC50:  2.30nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Ono Pharmaceutical

US Patent
LigandPNGBDBM238252(US10336741, Example 20 | US10882855, Example 20 | ...)
Affinity DataIC50:  3.20nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Ono Pharmaceutical

US Patent
LigandPNGBDBM406677(US10336741, Example 96)
Affinity DataIC50:  4.20nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Ono Pharmaceutical

US Patent
LigandPNGBDBM238260(US10336741, Example 73 | US10882855, Example 73 | ...)
Affinity DataIC50:  4.40nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Ono Pharmaceutical

US Patent
LigandPNGBDBM238265(US10336741, Example 94 | US10882855, Example 94 | ...)
Affinity DataIC50:  5.40nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Ono Pharmaceutical

US Patent
LigandPNGBDBM238263(US10336741, Example 88 | US10882855, Example 88 | ...)
Affinity DataIC50:  5.40nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Ono Pharmaceutical

US Patent
LigandPNGBDBM238261(US10336741, Example 79 | US10882855, Example 79 | ...)
Affinity DataIC50:  6.5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Ono Pharmaceutical

US Patent
LigandPNGBDBM238268(US10336741, Example 98 | US10882855, Example 98 | ...)
Affinity DataIC50:  7.40nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Ono Pharmaceutical

US Patent
LigandPNGBDBM238269(US10336741, Example 111 | US10882855, Example 111 ...)
Affinity DataIC50:  8.5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Ono Pharmaceutical

US Patent
LigandPNGBDBM294104(US10336741, Example 86 | US10882855, Example 86 | ...)
Affinity DataIC50:  9.90nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Ono Pharmaceutical

US Patent
LigandPNGBDBM238255(US10336741, Example 43 | US10882855, Example 43 | ...)
Affinity DataIC50:  11nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Ono Pharmaceutical

US Patent
LigandPNGBDBM238253(US10336741, Example 37 | US10882855, Example 37 | ...)
Affinity DataIC50:  13nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Ono Pharmaceutical

US Patent
LigandPNGBDBM238256(US10336741, Example 55 | US10882855, Example 55 | ...)
Affinity DataIC50:  14nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Ono Pharmaceutical

US Patent
LigandPNGBDBM238251(US10336741, Example 9 | US10882855, Example 9 | US...)
Affinity DataIC50:  17nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Ono Pharmaceutical

US Patent
LigandPNGBDBM238264(US10336741, Example 93 | US10882855, Example 93 | ...)
Affinity DataIC50:  18nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Ono Pharmaceutical

US Patent
LigandPNGBDBM238257(US10336741, Example 57 | US10882855, Example 57 | ...)
Affinity DataIC50:  27nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Ono Pharmaceutical

US Patent
LigandPNGBDBM406666(US10336741, Example 39)
Affinity DataIC50:  78nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor X(Homo sapiens (Human))
Ono Pharmaceutical

US Patent
LigandPNGBDBM238265(US10336741, Example 94 | US10882855, Example 94 | ...)
Affinity DataIC50: >3.30E+4nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProthrombin(Homo sapiens (Human))
Ono Pharmaceutical

US Patent
LigandPNGBDBM238265(US10336741, Example 94 | US10882855, Example 94 | ...)
Affinity DataIC50: >3.30E+4nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProthrombin(Homo sapiens (Human))
Ono Pharmaceutical

US Patent
LigandPNGBDBM238260(US10336741, Example 73 | US10882855, Example 73 | ...)
Affinity DataIC50:  3.70E+4nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProthrombin(Homo sapiens (Human))
Ono Pharmaceutical

US Patent
LigandPNGBDBM238261(US10336741, Example 79 | US10882855, Example 79 | ...)
Affinity DataIC50:  4.00E+4nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProthrombin(Homo sapiens (Human))
Ono Pharmaceutical

US Patent
LigandPNGBDBM238263(US10336741, Example 88 | US10882855, Example 88 | ...)
Affinity DataIC50:  5.70E+4nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProthrombin(Homo sapiens (Human))
Ono Pharmaceutical

US Patent
LigandPNGBDBM294112(US10336741, Example 99 | US10882855, Example 99 | ...)
Affinity DataIC50:  8.40E+4nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProthrombin(Homo sapiens (Human))
Ono Pharmaceutical

US Patent
LigandPNGBDBM238259(US10336741, Example 71 | US10882855, Example 71 | ...)
Affinity DataIC50:  9.40E+4nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor X(Homo sapiens (Human))
Ono Pharmaceutical

US Patent
LigandPNGBDBM238260(US10336741, Example 73 | US10882855, Example 73 | ...)
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProthrombin(Homo sapiens (Human))
Ono Pharmaceutical

US Patent
LigandPNGBDBM238253(US10336741, Example 37 | US10882855, Example 37 | ...)
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor X(Homo sapiens (Human))
Ono Pharmaceutical

US Patent
LigandPNGBDBM238257(US10336741, Example 57 | US10882855, Example 57 | ...)
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor X(Homo sapiens (Human))
Ono Pharmaceutical

US Patent
LigandPNGBDBM238261(US10336741, Example 79 | US10882855, Example 79 | ...)
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor X(Homo sapiens (Human))
Ono Pharmaceutical

US Patent
LigandPNGBDBM406666(US10336741, Example 39)
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProthrombin(Homo sapiens (Human))
Ono Pharmaceutical

US Patent
LigandPNGBDBM294104(US10336741, Example 86 | US10882855, Example 86 | ...)
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor X(Homo sapiens (Human))
Ono Pharmaceutical

US Patent
LigandPNGBDBM294104(US10336741, Example 86 | US10882855, Example 86 | ...)
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProthrombin(Homo sapiens (Human))
Ono Pharmaceutical

US Patent
LigandPNGBDBM406666(US10336741, Example 39)
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProthrombin(Homo sapiens (Human))
Ono Pharmaceutical

US Patent
LigandPNGBDBM238255(US10336741, Example 43 | US10882855, Example 43 | ...)
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor X(Homo sapiens (Human))
Ono Pharmaceutical

US Patent
LigandPNGBDBM238263(US10336741, Example 88 | US10882855, Example 88 | ...)
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProthrombin(Homo sapiens (Human))
Ono Pharmaceutical

US Patent
LigandPNGBDBM238257(US10336741, Example 57 | US10882855, Example 57 | ...)
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProthrombin(Homo sapiens (Human))
Ono Pharmaceutical

US Patent
LigandPNGBDBM238264(US10336741, Example 93 | US10882855, Example 93 | ...)
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor X(Homo sapiens (Human))
Ono Pharmaceutical

US Patent
LigandPNGBDBM238264(US10336741, Example 93 | US10882855, Example 93 | ...)
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor X(Homo sapiens (Human))
Ono Pharmaceutical

US Patent
LigandPNGBDBM238252(US10336741, Example 20 | US10882855, Example 20 | ...)
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor X(Homo sapiens (Human))
Ono Pharmaceutical

US Patent
LigandPNGBDBM238256(US10336741, Example 55 | US10882855, Example 55 | ...)
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProthrombin(Homo sapiens (Human))
Ono Pharmaceutical

US Patent
LigandPNGBDBM238256(US10336741, Example 55 | US10882855, Example 55 | ...)
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProthrombin(Homo sapiens (Human))
Ono Pharmaceutical

US Patent
LigandPNGBDBM238252(US10336741, Example 20 | US10882855, Example 20 | ...)
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProthrombin(Homo sapiens (Human))
Ono Pharmaceutical

US Patent
LigandPNGBDBM406677(US10336741, Example 96)
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor X(Homo sapiens (Human))
Ono Pharmaceutical

US Patent
LigandPNGBDBM406677(US10336741, Example 96)
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor X(Homo sapiens (Human))
Ono Pharmaceutical

US Patent
LigandPNGBDBM238251(US10336741, Example 9 | US10882855, Example 9 | US...)
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProthrombin(Homo sapiens (Human))
Ono Pharmaceutical

US Patent
LigandPNGBDBM238268(US10336741, Example 98 | US10882855, Example 98 | ...)
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor X(Homo sapiens (Human))
Ono Pharmaceutical

US Patent
LigandPNGBDBM238268(US10336741, Example 98 | US10882855, Example 98 | ...)
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProthrombin(Homo sapiens (Human))
Ono Pharmaceutical

US Patent
LigandPNGBDBM238251(US10336741, Example 9 | US10882855, Example 9 | US...)
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor X(Homo sapiens (Human))
Ono Pharmaceutical

US Patent
LigandPNGBDBM238259(US10336741, Example 71 | US10882855, Example 71 | ...)
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 56 total ) | Next | Last >>
Jump to: